Диссертация (1141092), страница 17
Текст из файла (страница 17)
Heidenreich; Penelope Solis; N. A. Mark Estes; Gregg C. Fonarow;Corrine Y. Jurgens; Joseph E. Marine; David D. McManus; Robert L. McNamara.//. — J Am Coll Cardiol. 2016; doi:10.1016/ j.jacc.2016.03.521.8. Apostolakis S., Lane D., Gao Y., Buller H., Lip G.Y. Performance of theHEMORR2HAGES, ATRIA and HAS-BLED bleeding risk prediction scores inanticoagulated patients with atrial fibrillation: The AMADEUS study.
// — J AmColl Cardiol 2012; 60: 861-867.9. Arbit E. Goldberg M. Annex 1 Summary of Product Characteristics Rivaroxaban.URL: http://www.xarelto.com/html/downloads/ Xarelto_Summary_of_Product_Characteristics_30 Sept 2008.pdf11010.Baber U., Howard V. J., Halperin J. L. et al. Association of chronic kidney diseasewith atrial fibrillation among adults in the United States: Reasons for Geographicand Racial Differences in Stroke (REGARDS) study. // Circ ArrhythmElectrophysiol — 2011.
— Vol. 4. — P. 26–32.11.Bahit M.C., Lopes R.D., Wojdyla D.M., Held C., Hanna M., Vinereanu D., HylekE.M., Verheugt F., Goto S., Alexander J.H., Wallentin L., Granger C.B.. Nonmajor bleeding with apixaban versus warfarin in patients with atrial fibrillation. //Heart. 2017 Apr; 103(8):623-628.12.Banerjee A., Lane D. A., Torp-Pedersen C. et al. Net clinical benefit of new oralanticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a «realworld» atrial fibrillation population: a modeling analysis based on a nationwidecohort study // Thromb Haemost — 2012.— Vol.
107.— P. 584–589.13.Barrett Y.C., Wang Z., Frost C., Shenker A. Clinical laboratory measurement ofdirect factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. //Thromb Haemost. 2010; 104:1263–1271.14.Bayer Pharma AG. Xarelto (Rivaroxaban) Xarelto® Summary of ProductCharacteristics – EU; 2013. URL: http://www.xarelto.com/en/information-onxarelto/summary-of-product-characteristics/15.Beyer-Westendorf J, Ageno W. Benefit-risk profile of non-vitamin K antagonistoral anticoagulants in the management of venous thromboembolism.
ThrombHaemost. 2014;16:113–128. Ridgefield,CT:BoehringerIngelheimPharmaceuticals; 2011.16.Boehringer Ingelheim Ltd. PRADAXA Monograph (Canada). 2014: 1–64.17.Boks A.L., Brommer E.J., Schalm S.W., Van Vliet H.H. Hemostasis andfibrinolysis in severe liver failure and their relation to hemorrhage. Hepatology.1986;6:79–86.18.Buccheri G, Ferrigno D, Ginardi C, Zuliani C. Haemostatic abnormalities in lungcancer: prognostic implications. Er J Cancer. 1997;33:50–55.19.Budnitz DS, Lovegrove MC, Shehab N, Richards CL.
Emergency hospital-izationsfor adverse drug events in older Americans. N Engl J Med 2011;365(21):2002-12.11120.Camm A. J. Atrial fibrillation and risk // Clin Cardiol 2012; 35, Suppl 1: 1–2.21.Camm A. J., Kirchhof P., Lip G. Y. et al. Guidelines for the management of atrialfibrillation: the Task Force for the Management of Atrial Fibrillation of theEuropean Society of Cardiology (ESC) European Heart Rhythm Association;European Association for Cardio-Thoracic Surgery // Eur Heart J — 2010.— Vol.31.— P. 2369–2429.22.Camm A.
J., Kirchhof P., Lip G. Y. et al. Guidelines for the management of atrialfibrillation: the Task Force for the Management of Atrial Fibrillation of theEuropean Society of Cardiology (ESC). Europace 2010; 12:1360–1420.23.Carreiro J, Ansell J. Apixaban, an oral direct Factor Xa inhibitor: awaiting theverdict. Expert Opin Investig Drugs. 2008;17:1937–1945.24.Christersson C. D-dimer and risk of thromboembolic and bleeding events inpatients with atrial fibrillation--observations from the ARISTOTLE trial.
// JThromb Haemost. 2014 Sep; 12(9):1401-12. doi: 10.1111/jth.12638. Epub 2014Jul 24.25.Connolly S. J., Ezekowitz M. D., Yusuf S.et al. Dabigatran versus warfarin inpatients with atrial fibrillation / N Eng J Med — 2009.— Vol. 361.— P. 1139–1151.26.Dager WE, Gosselin RC, Kitchen S, Dwyre D. Dabigatran effects on theinternational normalized ratio, activated partial thromboplastin time, thrombintime, and fibrinogen: a multicenter, in vitro study. Ann Pharmacother. 2012;46:1627–1236.27.Daniel E. Singer, MD. Methodologic Problems in the Assessment of Bleed Scores.// JACC Vol. 61, No.
4, 2013 January 29, 2013:479-84.28.Deitelzweig S. et al. Early Assessment of Bleeding-Related Hospital Readmissionsamong Non-Valvular Atrial Fibrillation Patients Treated with the New OralAnticoagulants Using an Electronic Medical Record Database in the U.S. // EurHeart J. 2015;36:Abstract Supplement 338, 1083.11229.Douxfils J., Chatelain C., Chatelain B., Dogne J.M., Mullier F. Impact of apixabanon routine and specific coagulation assays: a practical laboratory guide. // ThrombHaemost. 2013; 110:283–294.30.Ebner M., Peter A., Spencer C., Hartig F., Birschmann I., Kuhn J., Wolf M., WinterN., Russo F., Zuern C.S., Blumenstock G., Ziemann U., Poli S. Point-of-CareTesting of Coagulation in Patients Treated With Non-Vitamin K Antagonist OralAnticoagulants.
// Stroke. 2015; 46:2741-7.31.EHRA PRACTICAL GUIDE / Practical Guide on the use of non-vitamin Kantagonist anticoagulants in patients with non-valvular atrial fibrillation / UpdatedEuropean Heart Rhythm Association, European society of cardiology – Europacedoi:10.1093/europace/euv30932.EORP-AF, EURObservational Research Programme-Atrial Fibrillation FumagalliS. et al. JACC Clin Electrophysiol 2015.33.Ezekowitz M.D., Bridgers S.L., James K.E., et al. Veterans Affairs StrokePrevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in theprevention of stroke associated with nonrheumatic atrial fibrillation.
// N. Engl. J.Med. – 1992. – Vol. 327. P.1406–1412.34.Ezekowitz M.D., James K.E., Nazarian S.M., et al. Silent cerebral infarction inpatients with nonrheumatic atrial fibrillation. The Veterans Affairs StrokePrevention in Nonrheumatic Atrial Fibrillation Investigators. // Circulation. – 1995.– Vol.
92. – P. 2178–2182.35.Fang M.C., Chang Y.C., Hylek E.M. et al. Advanced age, anticoagulation intensity,and risk for intracranial hemorrhage among patients taking warfarin for atrialfibrillation. Ann Intern Med 2004;141:745-752.36.Fang M.C., Go A.S., Chang Y., et al. A new risk scheme to predict warfarinassociated hemorrhage: The ATRIA (Antic-oagulation and Risk Factors in AtrialFibrillation) Study.
// J Am Coll Cardiol 2011;58: 395–401.37.Flaker G, Ezekowitz M, Yusuf S, Wallentin L, Noack H, Brueckmann M, ReillyP, Hohnloser SH, Connolly S. Efficacy and safety of dabigatran compared towarfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation:113results from the RE-LY (Randomized Evaluation of Long-Term AnticoagulationTherapy) study. // J Am Coll Cardiol.
2012;59:854–855.38.Flaker GC, Belew K, Beckman K, et al. Asymptomatic atrial fibrillation:demographic features and prognostic information from the Atrial FibrillationFollow-up Investigation of Rhythm Management (AFFIRM) study. // Am Heart J2005; 149:657-63.39.Fox K.A.A., Piccini J.P., Wojdyla D., et al. Prevention of stroke and systemicembolism with rivaroxaban compared with warfarin in patients with non-valvularatrial fibrillation and moderate renal impairment. // Eur Heart J. 2011;doi:10.1093/eurheartj/ehr342.40.Friberg L., Benson L., Rosenqvist M., Lip G. Bleeding risk and thr HAS-BLEDscore: the Swedish AF cohort study.
// Eur. Heart J., 2012, 33 (12), 1500-1510.41.Friberg L., Rosenqvist M., Lip G.Y. Evaluation of risk stratification schemes foris-chaemic stroke and bleeding in 182 678 patients with atrial fibrillation: theSwedish Atrial Fibrillation Cohort study. // Eur Heart J 2012; 33: 1500–1510.42.Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, ReevesRA, LaCreta F.
Apixaban, an oral, direct factor Xa inhibitor: single dose safety,pharmacokinetics, pharmacodynamics and food effect in healthy subjects. // Br JClin Pharmacol. 2013; 75:476–487.43.Fuster V., Rydén L.E., Cannom D.S. et al. 2011ACCF/AHA/HRS FocusedUpdates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for theManagement of Patients With Atrial Fibrillation: A Report Of the AmericanCollege of Cardiology Foundation /American Heart Association Task Force onPractice Guidelines. // Circulation 2011; 123:e269–e367.44.Gage B.F., Yan Y., Milligan P.E., et al. Clinical classification schemes forpredicting hemorrhage: results from the National Registry of Atrial Fibrillation(NRAF).
// Am Heart J 2006; 151: 713–719.45.Gallego P., Roldan V., Torregrosa J.M., et al. Relation of the HAS-BLED bleedingrisk score to major bleeding, cardiovascular events and mortality in anticoagulatedpatients with atrial fibrillation. // Circ Arrhythm Electrophysiol 2012: 5: 312–318.11446.Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillationin adults: national implications for rhythm management and stroke prevention: theAnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA2001; 285: 2370–2375.47.Gorst-Rasmussen A., Lip G.Y.H.
and Larsen T.B. Rivaroxaban versus warfarinand dabigatran in atrial fibrillation: comparative effectiveness and safety in Danishroutine care. Pharmacoepid Drug Saf 2016; doi: 10.1002/pds.4034.48.Graham D.J., Reichman M.E., Wernecke M., Hsueh Y.H., Izem R., SouthworthM.R., Wei Y., Liao J., Goulding M.R., Mott K., Chillarige Y., MaCurdy T.E.,Worrall C., Kelman J.A.. Stroke, Bleeding, and Mortality Risks in ElderlyMedicare Beneficiaries Treated With Dabigatran or Rivaroxaban for NonvalvularAtrialFibrillation.JAMAInternMed.2016Oct3.doi:10.1001/jamainternmed.2016.5954.49.Harder S. Renal profiles of anticoagulants // J Clin Pharmacol — 2011 — Vol. 52- P.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
